UCB SA - Company Profile
Powered by 
All the data and insights you need on UCB SA in one report.
$295
- Save hours of research time and resources with
our up-to-date UCB SA Strategy Report
- Understand UCB SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Business Description
UCB SA (UCB) develops, manufactures, sells and distributes pharmaceuticals for the treatment of people living with severe neurological and immunological disorders. The company operates through one reportable business segment, namely, Biopharmaceuticals, which focuses on the development of products for the treatment of neurological and immunological disorders.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D focus on the development of novel medicines for treatment of neurological and immunological disorders. The company’s research base consists of three research centers at Braine-L'Alleud (Belgium), Boston (the US) and Slough (the UK). The company has eight development hubs in Braine-l’Alleud & HQ (Belgium); Leuven (Belgium); Monheim (Germany); Raleigh (U.S.) Slough; (U.K.) Boston (U.S.); Tokyo (Japan) and Shanghai (China). The company’s pipeline products target severe diseases and address unmet medical needs. UCB also collaborated with Microsoft to combine drug discovery and development capabilities with Microsoft's computational services, cloud, and artificial intelligence to accelerate drug discovery and development. The R&D activites majorly operates in Belgium, the United Kingdom, and the United States. In FY2022, the company spent approximately EUR1,670 million on its R&D activities, amounting to 30.3% of the company’s annual revenue.
Product Categories
Overview
Includes Zyrtec (cetirizine, including Zyrtec-D/Cirrus), Xyzal (levocetirizine) and other products. -Xyzal and Zyrtec are indicated for the treatment of allergic rhinitis, including persistent allergic rhinitis and urticaria.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes Cimzia (certolizumab pegol) and Evenity (romosozumab). - Cimzia is tumor necrosis factor (TNF) blocker approved for the treatment of Crohn’s disease; rheumatoid arthritis; psoriatic arthritis; axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis and ankylosing spondylitis. UCB markets and distributes Cimzia in partnership with Astellas in Japan. - Evenity (romosozumab), a bone forming monoclonal antibody for the treatment of osteoporosis. It is co-developed and co-commercialized by UCB and Amgen. -Bimzelx approved for the treatment of moderate to severe plaque psoriasis in adults.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Core product portfolio consists of Vimpat (lacosamide), Keppra (levetiracetam), Briviact (brivaracetam), Nayzilam (midazolam) and Neupro (rotigotine). - Vimpat is approved in the US as an adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 4 years of aged and older and is approved in Europe as monotherapy and adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy. Vimpat is available as film-coated tablets, syrup and solution for infusion. - Keppra is approved for the treatment of partial-onset seizures, epilepsy primary generalized tonic-clonic (PGTCS) with idiopathic generalized epilepsy and for myoclonic seizures with juvenile myoclonic epilepsy. - Briviact (brivaracetam) is indicated as adjunctive therapy for the treatment of partial-onset seizures. - Neupro (rotigotine) is approved for Parkinson’s disease and restless legs syndrome. - Nayzilam (midazolam), a nasal spray approved in the US for the treatment of acute, intermittent, and stereotypic episodes of seizure clusters, acute repetitive seizures in patients with epilepsy. - The company markets Keppra and Neurpro in partnership with Otsuka and Vimpat in partnership with Daiichi Sankyo in Japan.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Target Markets
Includes Germany, Spain, France (including French territories), Belgium, Italy, The UK and Ireland.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Target Markets
Includes, Japan, China, and Other countries.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer